Abbott’s FreeStyle Libre portfolio, the most widely used and reasonably priced continuous glucose monitoring system (CGM) in the United States, will now make more Medicare beneficiaries than ever before eligible for reimbursement when using it. According to Jared Watkin, executive vice president of Abbott’s diabetes care division, “FreeStyle Libre technology was designed from the beginning to be affordable and accessible.” “We’ve concentrated on emphasising the significant advantages of continuous glucose monitoring to assist patients with diabetes in managing their care simply and painlessly. By expanding access, Medicare is taking a huge step towards enabling more people to use FreeStyle Libre, allowing them to worry less and enjoy healthier, better lives.
Adults in America are increasingly more likely to have diabetes. In the United States, about 11 million persons older than 65 have diabetes. More than two million Medicare enrollees who have diabetes and take insulin may now be able to control their condition with FreeStyle Libre CGMs. “Giving Medicare insulin users access to CGMs, like the FreeStyle Libre systems, is a powerful affirmation that access to the best available, patient-centered technologies can optimise the clinical impact and safety of life-saving, established therapies like insulin,” said James Gavin III, M.D., Ph.D., chief executive officer and chief medical officer of Healing Our Village, Inc., an organisation that specialises in assisting economically disadvantaged, ethnically diverse, and medically underserved people.
Additionally, the extension enables Medicare members who experience troublesome hypoglycemia—a condition in which a person’s blood sugar is lower than normal and can cause fainting or unconsciousness—to be eligible for coverage of a FreeStyle CGM to help them manage their diabetes. Chuck Henderson, president and CEO of the American Diabetes Association, said, “We applaud Medicare’s decision to allow all insulin-dependent individuals as well as others who have a history of problematic hypoglycemia to have access to a continuous glucose monitor, a potentially life-saving tool for diabetes management.”
The FreeStyle Libre 3 system’s reader has just been approved by the US Food and Drug Administration (FDA). Abbott is aiming to add the FreeStyle Libre 3 system as quickly as possible to Medicare’s list of covered systems following the FDA’s approval of a standalone reader. More doctors than any other CGM recommend the FreeStyle Libre systems to their Medicare patients. To find out more about Abbott’s Medicare coverage, go to FreeStyle.Abbott.
FreeStyle Libre 14 day system: If the FreeStyle Libre 14 day system is not used in accordance with the labelling instructions, a severe low or high glucose event may be missed and/or a treatment choice may be made that leads to damage. Use a fingerstick value from a blood glucose metre to make treatment decisions if the values do not correspond to the symptoms or expectations.
FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use the FreeStyle Libre 2 or FreeStyle Libre 3 systems in accordance with the labelling instructions may result in missing a serious low or high glucose event and/or making a treatment decision, which may result in damage. Use a fingerstick reading from a blood glucose metre for treatment decisions if glucose alarms and results do not correspond to symptoms or expectations.
Connect with Us